問卷

TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center

Digestive System Department

更新時間:2025-10-18

王品貽
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

8Cases

2026-01-01 - 2032-03-10

Phase III

Active
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)
  • Condition/Disease

    Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Test Drug

    Retatrutide (LY3437943) Tirzepatide (LY3298176)

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2025-01-01 - 2029-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2025-12-04 - 2028-12-23

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-12-04 - 2029-12-24

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting7Sites

2026-02-06 - 2032-09-25

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2026-02-12 - 2033-10-12

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2025-01-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2025-01-01 - 2030-01-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites